Shukri David

Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial

David E. Kandzari, Michael Böhm, Felix Mahfoud et al. · The Lancet · 2018 · 750 citations

Hypertension, Urology, Renal Function +10

Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial

Raymond R. Townsend, Felix Mahfoud, David E. Kandzari et al. · The Lancet · 2017 · 718 citations

Hypertension, Urology, Renal Function +10

Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial

Michael Böhm, Kazuomi Kario, David E. Kandzari et al. · The Lancet · 2020 · 555 citations

Antihypertensive Medications, Hypertension, Urology +9

Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial

Deepak L. Bhatt, Muthiah Vaduganathan, David E. Kandzari et al. · The Lancet · 2022 · 166 citations

Hypertension, Urology, Resistant Hypertension +10

Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation

Felix Mahfoud, Raymond R. Townsend, David E. Kandzari et al. · Journal of the American College of Cardiology · 2021 · 104 citations · Full text